8-K filings and company releases
Company news
3 articles on SELLAS Life Sciences Group.
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
SLS articles
Newest first, 25 to a page- Company release
Nov 20, 2026 · Company release
SELLAS Life Sciences Group closes public offering for $172.5 million gross
The offering included the full exercise of the underwriters' option to buy 1,730,769 additional shares at $13.00 per share.
- Form 8-K and release
Nov 17, 2026 · Form 8-K and release
SELLAS Life Sciences Group prices 11,538,462-share offering at $13.00 per share
The company said it expects gross proceeds of $150.0 million before underwriting discounts and commissions and offering expenses.
- Form 8-K and release
Nov 17, 2026 · Form 8-K and release
SELLAS says Phase 3 REGAL trial of galinpepimut-S met its primary endpoint in AML
In the trial, the cancer vaccine reduced the risk of death by 41% compared with best available treatment.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.
